The COVID-19 pandemic will end, or as any pandemic in the past, will lose its momentum. Yet, the precedents and the new paradigms formed in clinical research as a result of it will last.
Read More
Join AMR experts from Medpace, IHMA, and GARDP as they discuss how we can use the momentum from the pandemic to rethink, rebuild and revitalize the pipeline for antibacterial drugs.
Read More
An in-depth look at infectious diseases including hematologic malignancies in immunocompromised patients and the unique challenges for clinical development.
Read More
Nothing derails a clinical study timeline more than poor planning and not anticipating and preparing for potential roadblocks. While you may not be able to anticipate everything, many of the risks and challenges can be averted if you understand the landscape and prepare accordingly.
Read More
Medpace and Diversigen discuss the opportunities and challenges of the microbiome in clinical trials in a recently published whitepaper. You can access the whitepaper in its entirety here.
Read More
In this post, Dr. Brian Murphy, Vice President of Medical Affairs for Infectious Diseases, discusses the following topic: “Source Control Review in Clinical Trials of Anti-infective Agents in Complicated Intra-abdominal Infections”
Read More
Recent discoveries have been made that have revealed the power of microbes to prevent, diagnose, and treat disease. As a result of these discoveries, clinical developers are trying to harness these insights in order to develop new medical therapeutics.
Read More